Objective: To investigate the feasibility of radioimmunoimaging (RII) on the nude mice model by labelling anti-ovarian carcinoma monoclonal antibody (McAb, COC166-9) with 99mTc, and the possibility for clinical application.
Methods: McAb reduced by beta-mercaptoethanol was labelled directly with 99mTc. Imaging positive rate, negative rate and tumor/non-tumor (T/N) ratio were calculated.
Results: (1)McAb COC166-9 labelled with 99mTc reacted with ovarian carcinoma. (2) 8 nude mice models were injected with the labelled antibodies and were then imaged. In the experimental group the positive imaging rate of tumor was 100%, in the control group the negative rate was 100%. The results were the same as those of T/N ratios. (3)In two groups (10 nude mice), intraperitoneal (i.p.) or intravenous (i.v.) injection of McAb labelled with 99mTc, positive imaging rates of tumor 100%. The IV group was better than IP group in the radio-background.
Conclusions: Immunoactivity of 99mTc-COC166-9 used for RII on the nude mice models was good, and the imaging effect was specific. Clinical application is promising.